Therapeutics News and Research

RSS

Harbor BioSciences closes U.S.-based Apoptone Phase I/IIa clinical trial for castration resistant prostate cancer

Harbor BioSciences, Inc., a biopharmaceutical company developing novel therapeutics for the treatment of cancer, metabolic and inflammatory diseases, today announced it is closing the clinical sites of its U.S.-based Phase I/IIa clinical trial with Apoptone® (HE3235) for castration resistant prostate cancer (CRPC) – also referred to as hormone resistant prostate cancer.

7 Feb 2011

Human Vaccines journal publishes paper on Inovio's new DNA vaccine delivery technology

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that its new generation DNA vaccine delivery technology, which provides the powerful enabling capabilities of electroporation without contacting the skin, is highlighted in a paper published in the scientific journal Human Vaccines.

7 Feb 2011

Diabetes Management – a new journal addressing the management issues of a complex disease

Future Medicine Ltd has today announced the launch of Diabetes Management – a new bimonthly title presenting findings, analyses and commentaries on the battle with Type 1 and Type 2 diabetes. Diabetes Management is published by Future Medicine Ltd (UK, London) renowned for its collection of journals providing healthcare practitioners and research professionals with a unique source of objective, cutting-edge information on exciting trends emerging in light of advances in medicine, healthcare and clinical practice.

6 Feb 2011

Ameritox makes significant strides to advance its industry leadership position

Ameritox, the nation's leader in pain medication monitoring, made significant strides to advance its industry leadership position by strengthening the company's commitment to physicians and patients in the past twelve months.

5 Feb 2011

Onset Therapeutics announces corporate name change to Onset Dermatologics

Onset Therapeutics, a PreCision Dermatology company and a leader in the development and commercialization of novel, prescription products for the treatment of skin disorders, today announced that it has changed its corporate name to Onset Dermatologics.

5 Feb 2011

EntreMed announces publication of ENMD-2076 Phase 1 results against solid tumors in AACR journal

EntreMed, Inc., today announced the publication of key papers on the clinical and preclinical development of ENMD-2076, an Aurora A/angiogenic kinase inhibitor. The clinical data were published in the December 3, 2010 on-line issue of the American Association for Cancer Research journal, Clinical Cancer Research, and are expected to appear soon in the print version of the publication.

4 Feb 2011

Engineered cells take control of the cells and microenvironment following transplantation

In work that could jumpstart the promising field of cell therapy, in which cells are transplanted into the body to treat a variety of diseases and tissue defects, researchers at Brigham and Women's Hospital (BWH) have engineered cells that could solve one of the key challenges associated with the procedure: control of the cells and their microenvironment following transplantation.

4 Feb 2011

Digna Biotech, CIMA receive EU grant for development of gene therapy product for Acute Intermittent Porphyria

Digna Biotech and the Centro de Investigacion Medica Aplicada (CIMA) de la Universidad de Navarra announced today that the European Union (EU) has finalized a EUR 3.3 million grant to AIPGENE consortium. Digna Biotech and CIMA will receive, as members of the consortium, EUR 0.5 and EUR 0.8 million respectively for the clinical development of a gene therapy product for Acute Intermittent Porphyria (AIP).

4 Feb 2011

Cholesterol efflux capacity may protect against heart disease: Study

The discovery that high levels of high-density lipoprotein cholesterol are associated with reduced risk of cardiovascular disease has fostered intensive research to modify HDL levels for therapeutic gain. However, recent findings have called into question the notion that pharmacologic increases in HDL cholesterol levels are necessarily beneficial to patients.

4 Feb 2011

Tacere announces reacquisition of HCV compound development, commercialization rights in Asia

Tacere Therapeutics, an RNA interference (RNAi)-based therapeutics company, announced today that it has reacquired the development and commercialization rights to its Hepatitis C Virus compounds throughout Asia from its strategic partner, Tokyo-based Oncolys BioPharma Inc.

4 Feb 2011

Repros prices public offering of 2,760,000 shares of common stock

Repros Therapeutics today announced the pricing of its public offering of 690,000 units, consisting of 2,760,000 shares of its common stock, Series A Warrants to purchase 2,070,000 shares of common stock and Series B Warrants to purchase 1,690,500 shares of its common stock, at a price per unit of $17.15.

3 Feb 2011

Nitto Denko announces acquisition of Avecia Biotechnology

Japan's leading diversified materials manufacturer, Nitto Denko Corporation, today announced that it has acquired Avecia Biotechnology, Inc. through Nitto Americas, Inc., a wholly owned subsidiary in Teaneck, New Jersey.

3 Feb 2011

Concert and WRAIR enter CRADA to evaluate novel compound for seizure protection associated with TBI

Concert Pharmaceuticals, Inc. today announced that it has entered into a Cooperative Research and Development Agreement with the Walter Reed Army Institute of Research. The CRADA will allow the WRAIR to conduct preclinical testing on a novel compound derived from Concert's DCE Platform™ (deuterated chemical entity platform) for seizure protection associated with traumatic brain injury, a major public health concern.

3 Feb 2011

ImmunoCellular Therapeutics initiates enrollment in ICT-107 Phase II trial for GBM

ImmunoCellular Therapeutics, Ltd., a biotechnology company that is developing immune-based therapies for the treatment of various forms of cancer, announced today that the first patient has been enrolled in its Phase II trial of ICT-107 at the New Jersey Neuroscience Institute at JFK Medical Center. ICT-107 is the company's dendritic cell based cancer vaccine candidate for the treatment of glioblastoma multiforme (GBM).

3 Feb 2011

FDA disallows obesity drug Contrave pending further large-scale testing

In its latest blow to obesity medication development efforts, the US Food and Drug Administration (FDA) yesterday notified Orexigen Therapeutics that it would need to conduct an extremely large-scale study of the long-term cardiovascular effects of its drug, Contrave, before approval could be considered.

3 Feb 2011

Scil Proteins concludes financing round with BioNet Holding for €24 million

Scil Proteins today announced that it has concluded a financing round with its existing investor, BioNet Holding, worth €24 million. The funds are intended to finance the development of two products derived from the Company's Affilin platform into clinical Phase I over the next three years.

2 Feb 2011

Five young scientists receive Damon Runyon-Rachleff Innovation Award for cancer research

The Damon Runyon Cancer Research Foundation announced that five scientists with novel approaches to fighting cancer have been named 2011 recipients of the Damon Runyon-Rachleff Innovation Award. The grant of $450,000 over three years is awarded each year to early career scientists whose projects have the potential to significantly impact the prevention, diagnosis and treatment of cancer.

2 Feb 2011

Damaged heart rebuilt with heart stem cells from children with congenital heart disease

A new study, revealing that heart stem cells from children with congenital heart disease were able to rebuild the damaged heart in the laboratory, could provide a new outlet for Emerging Healthcare Solutions' NASA bioreactor.

2 Feb 2011

Harbor BioSciences announces publication of newly discovered anti-inflammatory steroids

Harbor BioSciences, a biopharmaceutical company developing novel therapeutics for the treatment of cancer, metabolic and inflammatory diseases, today announced publication of newly discovered anti-inflammatory steroids naturally present in humans.

2 Feb 2011

Aphios enters subcontract with SAIC-Frederick to develop phospholipid nanoencapsulated camptothecin

Aphios® Corporation today announced that it has entered into a subcontract with SAIC-Frederick, a subsidiary of Science Applications International Corporation, to develop phospholipid nanoencapsulated camptothecin, Camposomes™, for the treatment of pancreatic and other cancers, supporting the NCI Alliance for Nanotechnology.

2 Feb 2011

Therapeutics News and Research

Harbor BioSciences closes U.S.-based Apoptone Phase I/IIa clinical trial for castration resistant prostate cancer

Human Vaccines journal publishes paper on Inovio's new DNA vaccine delivery technology

Diabetes Management – a new journal addressing the management issues of a complex disease

Ameritox makes significant strides to advance its industry leadership position

Onset Therapeutics announces corporate name change to Onset Dermatologics

EntreMed announces publication of ENMD-2076 Phase 1 results against solid tumors in AACR journal

Engineered cells take control of the cells and microenvironment following transplantation

Digna Biotech, CIMA receive EU grant for development of gene therapy product for Acute Intermittent Porphyria

Cholesterol efflux capacity may protect against heart disease: Study

Tacere announces reacquisition of HCV compound development, commercialization rights in Asia

Repros prices public offering of 2,760,000 shares of common stock

Nitto Denko announces acquisition of Avecia Biotechnology

Concert and WRAIR enter CRADA to evaluate novel compound for seizure protection associated with TBI

ImmunoCellular Therapeutics initiates enrollment in ICT-107 Phase II trial for GBM

FDA disallows obesity drug Contrave pending further large-scale testing

Scil Proteins concludes financing round with BioNet Holding for €24 million

Five young scientists receive Damon Runyon-Rachleff Innovation Award for cancer research

Damaged heart rebuilt with heart stem cells from children with congenital heart disease

Harbor BioSciences announces publication of newly discovered anti-inflammatory steroids

Aphios enters subcontract with SAIC-Frederick to develop phospholipid nanoencapsulated camptothecin

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News